Aveo ends trial of cancer drug due to low enrollment

|By:, SA News Editor

Aveo Oncology (AVEO) and Japanese partner Astellas Pharma (ALPMF) plan to end a Phase II study of the Tivozanib drug for treating breast cancer after not being able to enroll enough patients in the trial.

The latest blow to Aveo comes after the FDA rejected Tivozanib as a treatment for kidney cancer in June, due to inconsistent study results. (PR)